Cemiplimab monotherapy as first-line treatment of patients with brain metastases from advanced non–small cell lung cancer with programmed cell death-ligand 1 ≥50%
Küçük Resim Yok
Tarih
2024
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
John wiley and sons inc
Erişim Hakkı
info:eu-repo/semantics/closedAccess
Özet
Cemiplimab monotherapy as first-line treatment of patients with brain metastases from advanced non–small cell lung cancer with programmed cell death-ligand 1 ≥50%
Açıklama
Anahtar Kelimeler
Advanced NSCLC, Brain Metastases, Cemiplimab, Immunotherapy, PD-L1
Kaynak
Cancer
WoS Q Değeri
Q1
Scopus Q Değeri
Q1
Cilt
19
Sayı
10
Künye
Kilickap, S., Sezer, A., Özgüroğlu, M., Gumus, M., Bondarenko, I., Gogishvili, M., ... & Magnan, H. (2024). OA11. 06 Cemiplimab Monotherapy for First Line Advanced NSCLC Patients with PD-L1 Expression≥ 50%: 5-y Outcomes of EMPOWER-Lung 1. Journal of Thoracic Oncology, 19(10), S35.
